Long-term improvement of dyslipidaemia, hyperuricemia and metabolic syndrome in patients undergoing laparoscopic sleeve gastrectomy

Objective: The aim of the study was to assess the long-term impact of laparoscopic sleeve gastrectomy (LSG) on lipid profile, uric acid level and metabolic syndrome. Materials and methods: A prospective study was performed between 2009-2014, evaluating long-term percentage of excesso body mass index...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of Endocrinology and Metabolism 2021-05, Vol.64 (6), p.704-709
Hauptverfasser: Zetu, Cornelia, Popa, Simona, Golli, Andreea-Loredana, Condurache, Ancuta, Munteanu, Rubin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: The aim of the study was to assess the long-term impact of laparoscopic sleeve gastrectomy (LSG) on lipid profile, uric acid level and metabolic syndrome. Materials and methods: A prospective study was performed between 2009-2014, evaluating long-term percentage of excesso body mass index loss (%EBMIL), lipid profile, uric acid level and metabolic syndrome. Results:Overall sixty subjects were followed-up. %EBMIL increased significantly, reaching a maximum (86,9 +/- 6,3%) at 5 years post-LSG. Therapeutic success rate (%EBMIL >= 60%) was 80% at 5 years. The triglyceride level decreased significantly (148 +/- 72.1 mg/dL baseline vs 130.7 +/- 57.5 mg/dL at 1 month vs 110.7 +/- 42.6 mg/dL at 3 months vs 92.5 +/- 35.2 mg/dL at 1 year vs 84.2 +/- 32.3 mg/dL at 5 years; p < 0.05 for all). HDL-cholesterol increased and uric acid decreased significantly in the first year postoperatively, remaining stable afterwards (46.9 +/- 12.3 mg/dL baseline vs 47.4 +/- 10 mg/dL at 1 month vs 49.8 9.3 mg/dL at 3 months vs 55.4 +/- 10.2 mg/dL at 1 year; p < 0.05 for all for HDL-cholesterol and 6.4 +/- 2 mg/dL baseline vs 6 +/- 13 mg/dL at 1 month vs 5.2 +/- 1.3 mg/dL at 3 months vs 4.8 +/- 1 mg/dL at 1 year; p < 0.05 for all for uric acid).The prevalence of metabolic syndrome decreased from 66.7% baseline to 8.3% at 5 years postoperatively (p < 0.01). Conclusions: LSG was effective in terms of %EBMIL and metabolic traits improvement for Romanian patients.
ISSN:2359-3997
2359-4292
DOI:10.20945/2359-3997000000273